Comparing bladder medication vs surgery for returning low-grade bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your previous bladder tumor was low-grade and has come back
- The new tumor must be smaller than 2 cm (about 0.8 inches)
- You have not had chemotherapy or BCG treatment in the bladder before (except a single dose after surgery)
- You are not allergic to the drug mitomycin C
- You are not pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an outpatient laser procedure to remove recurring low-grade, non-solid bladder tumors. It may help prevent or control tumor growth with treatment done outside the hospital, if you meet the tumor and health criteria.
This trial tests a new, precise way to use chemotherapy to remove low-risk, non-muscle-invasive bladder tumors before surgery. It may be an option for people with small, slow-growing tumors that haven't spread into the bladder muscle.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.